WO2000005252A1 - Vaccin comportant un derive immunogene non toxique de la neurotoxine clostridium botulinum du type d - Google Patents
Vaccin comportant un derive immunogene non toxique de la neurotoxine clostridium botulinum du type d Download PDFInfo
- Publication number
- WO2000005252A1 WO2000005252A1 PCT/IB1999/001301 IB9901301W WO0005252A1 WO 2000005252 A1 WO2000005252 A1 WO 2000005252A1 IB 9901301 W IB9901301 W IB 9901301W WO 0005252 A1 WO0005252 A1 WO 0005252A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bont
- botulinum type
- derivative
- immunogenic
- fragment
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims abstract description 92
- 241000193155 Clostridium botulinum Species 0.000 title claims abstract description 86
- 231100000252 nontoxic Toxicity 0.000 title claims abstract description 59
- 230000003000 nontoxic effect Effects 0.000 title claims abstract description 59
- 239000002581 neurotoxin Substances 0.000 title claims abstract description 26
- 231100000618 neurotoxin Toxicity 0.000 title claims abstract description 26
- 101710138657 Neurotoxin Proteins 0.000 title claims abstract description 23
- 229960005486 vaccine Drugs 0.000 title claims description 30
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 82
- 239000012634 fragment Substances 0.000 claims abstract description 82
- 239000002773 nucleotide Substances 0.000 claims abstract description 48
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 46
- 230000035772 mutation Effects 0.000 claims abstract description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 17
- 108020004414 DNA Proteins 0.000 claims abstract description 14
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 52
- 239000013598 vector Substances 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 208000003508 Botulism Diseases 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 238000002255 vaccination Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 208000005374 Poisoning Diseases 0.000 claims description 4
- 231100000572 poisoning Toxicity 0.000 claims description 4
- 230000000607 poisoning effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 description 61
- 241000193764 Brevibacillus brevis Species 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 32
- 239000013612 plasmid Substances 0.000 description 28
- 239000002609 medium Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 239000012228 culture supernatant Substances 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108700005078 Synthetic Genes Proteins 0.000 description 9
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 229960003276 erythromycin Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241001331845 Equus asinus x caballus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000143060 Americamysis bahia Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010009004 proteose-peptone Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108010044241 tetanus toxin fragment C Proteins 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000007739 pm medium Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to immunogenic derivatives of
- Clostridium botulinum neurotoxin DNA encoding such derivatives
- immunogenic botulinum neurotoxin derivatives vaccines for combating C.
- botulinum neurotoxins methods for the preparation of immunogenic derivatives of C. botulinum neurotoxin and to methods for the preparation
- Clostridium botulinum is a species of the large bacterial genus
- Clostridium Bacteria belonging to this genus are spore-forming anaerobic
- Gram positive bacilli The species C. botulinum can be sub-divided into types and the different types produce several toxins, e.g. such as types A,
- Types C and D are generally pathogenic to cattle, sheep, pigs,
- BoNT neurotoxin
- Pathogenesis or poisoning usually results after the ingestion of carrion or decomposed material contaminated with BoNT
- Clostridial neurotoxins are one of the
- the target sites of the BoNT are the cholinergic nerve endings of neurons in the animal.
- the BoNT affects
- BoNT is a protein with an approximate molecular
- BoNT may be viewed as being composed of three
- Botulism vacines currently available are generally
- botulinium vacine production strains low levels of toxin production
- Non-toxic is defined as the intra peritoneal injection of 0.2 ml of the
- the derivative or immunogenic fragment thereof may carry a
- sequence ID No. 1 or a fragment, analog or derivative thereof.
- sequence ID No. 2 amino acids 1 to 399 or a fragment, analog or
- the invention provides a non-toxic immunogenic
- amino acid sequence which is at least 75%, more preferably
- immunogenic fragment thereof is understood to be a fragment that, although not comprising the full length amino acid sequence of the
- derivative of the type D neurotoxin still comprises regions of the derivative
- a mutation is understood to be a change in the nucleic acid
- the mutation may be a replacement
- mutation can e.g. be such that one or more amino acids of the type D
- BoNT are replaced by other amino acids, with different characteristics.
- the invention also relates to derivatives of type D BoNT
- Non-toxic immunogenic derivatives of type D BoNT according to the invention may be made by introducing mutations in the gene encoding the
- the mutated DNA fragments may then be cloned in a nucleotide sequence, such as a suitable expression plasmid and
- nucleotide sequence comprising a mutated or recombinant DNA fragment
- the invention provides a nucleic acid characterised by
- sequence ID No. 2 (nucleotides 58 to 1 254), or a fragment of said
- the invention provides a nucleic acid comprising a
- nucleotide sequence which encodes a non-toxic immunogenic derivative
- nucleotide sequence being selected from the group consisting of sequence
- sequence ID No. 1 sequence ID No. 2 (nucleotides 58 to 1 254), and a fragment of
- the invention comprises a nucleotide sequence
- polynucleotide having at least 75%, preferably 85%, identity
- polynucleotide encoding a non-toxic immunogenic derivative of C.
- the invention comprises a nucleotide sequence
- polynucleotide having at least 75%, preferably 85%, identity
- polynucleotide encoding a genetically non-toxic immunogenic
- the polynucleotide may be DNA or RNA.
- the polynucleotide may be DNA or RNA.
- polynucleotide is plasmid DNA.
- a suitable bacterial expression system for expressing the non-toxic immunogenic derivatives of type D BoNT according to the invention are
- Gram positive bacteria such as Bacillus brevis, Bacillus subtilus or Gram negative bacteria such as Escherichia coli. It is also envisaged that other members of the plant.
- expression systems may be used for expressing non-toxic immunogenic
- suitable yeast expression system for example Pichia pastoris.
- positive bacterial expression system comprising a nucleotide sequence according to the invention encoding a non-toxic immunogenic derivative
- negative bacterial expression system comprising a nucleotide sequence according to the invention encoding a non-toxic immunogenic derivative
- said vaccine comprising a non-toxic immunogenic derivative
- Such vaccines may be made by admixing an immunologically sufficient amount of a non-toxic immunogenic derivative or derivatives of
- Still another embodiment of the invention relates to vaccines for protection against botulinum caused by C. botulinum type D BoNT that
- BoNT according to the invention or an immunogenic fragment thereof
- one or more compounds having adjuvant activity may be any one or more compounds having adjuvant activity.
- one or more compounds having adjuvant activity may be any one or more compounds having adjuvant activity.
- the vaccine e.g. Alhydrogel, Alum or Saponin.
- the vaccine may be administered to all hosts sensitive to C.
- botulinum type D BoNT such as cattle, mules, sheep, goats, horses, birds, humans, etc.
- dosage is administered once and may be repeated after a month or two.
- Non-toxic immunogenic derivatives of C. botulinum type D BoNT are nucleotide sequence according to the invention.
- Non-toxic immunogenic derivatives of C. botulinum type D BoNT are nucleotide sequence according to the invention.
- the non-toxic immunogenic amino acids of the polypeptide or protein are acids of the polypeptide or protein.
- the non-toxic immunogenic amino acids of the polypeptide or protein are acids of the polypeptide or protein.
- derivatives may also be prepared by introducing mutations in the gene or
- non-toxic immunogenic derivatives may be prepared
- recombinant DNA or fragments thereof may then be cloned in a nucleotide
- sequence such as a suitable expression vector
- D BoNT poisoning which method comprises admixing a non-toxic compound
- the vaccine may be administered by a variety of suitable routes
- sequence of sequence ID No. 2 amino acids 1 to 399.
- the invention provides a vector which includes a
- nucleotide sequence according to the invention which encodes a non-toxic
- the invention also extends to a host cell genetically engineered with
- the host cell may be any suitable host cell as a yeast or bacterium.
- the host cell may be B. subtilus, E. coli. or B. brevis, e.g. B.
- the vector may be any suitable vector known in the art, such as a suitable plasmid.
- the invention also extends to a method for preparing a non-toxic vector
- nucleotide sequence encoding a non-toxic amino acid sequence
- the invention also provides a method for preparing a non-toxic compound
- the nucleotide sequence may be a polynucleotide of sequence ID
- sequence ID No. 2 nucleotides 58 to 1 254.
- the nucleotide sequence may be expressed under the control of its
- the Gram positive bacterium may be selected from the group consisting of Bacillus brevis and Bacillus subtilus.
- the Gram negative bacterium may be E. coli. According to yet another aspect of the invention, there is provided
- substance or composition for use in a method of vaccinating an animal against C. botulinum type D BoNT, said substance or composition
- Figure 1 shows the structure of a suitable expression-secretion
- the closed bar indicates the 5 region of the MWP gene containing
- MCS multiple cloning site
- SD 1 and SD2 are the ribosome-binding sites located
- Figure 2 is a genetic map of a gene in accordance with the invention.
- Figure 3 is a genetic map indicating sequencing coverage
- sequence primer location includes a list of primers used and their
- Figure 4 is an analysis of recombinant plasmids through comparative
- Lane 1 represents DNA molecular weight
- Lanes 2 and 4 represent plasmid extractions from B.
- the arrows indicating the DNA fragments of 1 207 bp, represent the genes according to the invention as digested from
- Figure 5 is a PAGE electrophoretogram of B. brevis culture supernatant demonstrating secretion of recombinant heterologous COOH-
- Lane 1 represents the protein profile of the culture supernatant of a B. brevis strain transformed with PNU 21 1 without the gene fragment
- Figure 6 is a Western blot analysis of a PAGE protein profile of B.
- Lane 1 represents the
- Lane 4 represents the protein
- Figure 7 is a growth curve of a fermentation culture of B. brevis
- Sequence ID No. 1 is a nucleotide sequence of a synthetic gene
- Sequence ID No. 2 shows a nucleic acid sequence of a gene
- sequence ID No. 2 nucleotide and amino acid sequences
- a novel nucleotide sequence or gene according to the invention encoding a non-toxic immunogenic derivative of C. botulinum type D toxin
- nucleotide sequence or gene was redesigned to have the optimal codons
- Bacterial strains and vectors Bacterial strains and vectors.
- Bacillus brevis strain Bacillus brevis strain
- Plasmid PNU 21 1 was obtained from S Udaka, Department of Applied Biological Sciences, Nagoya University, Japan..
- Clones were selected by growth on LB agar plates supplemented with 50
- Plasmid extractions were performed according to the method of Reference 1 9. Plasmids were
- ECL Western blotting detection reagents and ECL protein molecular weight markers were obtained from Amersham International.
- DAB substrate kit was obtained from Zymed Laboratories Inc. Difco
- the gene according to the invention was designed
- Hind III were included for cloning purposes.
- the gene was synthesized and cloned into a suitable vector
- Antiserum used for immunoblots was prepared by hyper-immunization of horses against C. botulinum serotype D neurotoxin (OBP). Antibodies
- Bacillus brevis recombinants Bacillus brevis recombinants.
- Clones were selected by growth on LB agar plates
- Plasmids were digested with restriction enzymes Pst I and Hind III and analyzed on a 1 % agarose gel to confirm the presence of the gene
- Bacillus brevis strain 47- 5Q (JMC no. 8970) was transformed with PNU 21 1 according to the instructions of the manufacturer.
- Clones were selected by growth on T2U plates
- the gene fragment insert were screened by immuno colony blot analysis.
- lysing buffer 50 mM Glucose
- botulinum antiserum type D 1000 units/ml was diluted 1 : 200 in TBS ( 1 % milk powder) and used
- DAB tetrahydrochloride
- Modified PY medium 100 ml was inoculated
- PAGE electrophoresis PAGE electrophoresis (Bio-Rad Mini Protean II) on a 5% gel were
- destain solution 300 ml ethanol, 80 ml glacial acetic acid, 620
- antiserum type D 1000 units/ml was, after adsorption, diluted 1 :200 and
- HRP horseradish peroxidase conjugated Protein G was diluted 1 : 3000 and used as secondary antibody.
- LumiAnalyst Image Analysis software program (Boehringer Mannheim).
- T2U medium 100 ml was
- the culture supernatant was mixed in a 1 : 1 ratio with 50 % Aluminium
- OBP Hydroxide adjuvant
- mice weighing 1 8 g to 20 g. The mice were each injected subcutaneously with 0.2 ml. After 21 days, two groups of 5 immunized mice and 1 0 control mice each, were challenged with OBP C. botulinum type D standard
- mice One group of immunized mice and one group control mice
- mice were injected intraperitoneally into each of the mice with 0. 2 ml of toxin diluted in saline to give a final concentration of 0.05 U.
- the other group
- mice were observed for 24 h for survival, signs of botulism or death.
- the size of the gene is 1 207 bp and the resulting protein
- the %GC content is 34.6 %, compared to the %GC of B. brevis of 42.7 to 47 % (Reference 27) and to that of C. botulinum of
- Bacillus brevis recombinants Bacillus brevis recombinants.
- transformants (B. brevis 1 1 5) was cultured on modified PY-medium and
- production medium used as a 20 % inoculum for 10 liter medium in the
- Figure 7 represents the growth curve of a typical fermenter run.
- the fermenter was set at maximum value for oxygen saturation.
- polypeptide according to the invention in the formulation of a vaccine
- mice used to vaccinate mice. Mice challenge studies with 0.03 U and 0.05 U toxin, 21 days after vaccination, resulted in death of all the control mice
- botulinum type D BoNT botulinum type D BoNT. This method of vaccine production would involve fermenter technology, a unique method for botulism type D vaccine
- the vaccines can be produced or manufactured relatively quickly and the
- vaccine is non-toxic perse. Since the product of the fermentation process
- Kiyatkin, N., Maksymowych, A. B. and Simpson, L. L. ( 1 997) .
- serotype B expressed in the methylotrophic yeast Pichia pastoris.
- Toxicon Vol.36, p. 1539-1548.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU46412/99A AU4641299A (en) | 1998-07-22 | 1999-07-20 | Vaccine comprising a non-toxic immunogenic derivative of (clostridium botulinum)type d neurotoxin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA986538 | 1998-07-22 | ||
ZA98/6538 | 1998-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000005252A1 true WO2000005252A1 (fr) | 2000-02-03 |
Family
ID=25587157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1999/001301 WO2000005252A1 (fr) | 1998-07-22 | 1999-07-20 | Vaccin comportant un derive immunogene non toxique de la neurotoxine clostridium botulinum du type d |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4641299A (fr) |
WO (1) | WO2000005252A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002008268A2 (fr) * | 2000-07-21 | 2002-01-31 | Allergan, Inc. | Motif a base de leucine et neurotoxines clostridiales |
US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US7691983B2 (en) | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
US8445650B2 (en) | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
WO2019126542A1 (fr) * | 2017-12-20 | 2019-06-27 | Allergan, Inc. | Polypeptides du domaine de liaison cellulaire de toxine botulique et procédés d'utilisation pour des traitements de troubles associés à la fibrose |
WO2019152380A1 (fr) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production de neurotoxines de botulinum à l'aide de systèmes bacillus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4292307A (en) * | 1977-09-30 | 1981-09-29 | Zemlyakova Valentina P | Vaccine and method for prophylaxis and treatment of clostridioses of animals and poultry |
WO1996041881A1 (fr) * | 1995-06-12 | 1996-12-27 | Microbiological Research Authority | Toxine botulinique de type f et son utilisation |
WO1998007864A1 (fr) * | 1996-08-23 | 1998-02-26 | Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) | Fragments de toxines recombines |
WO1998008540A1 (fr) * | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | VACCIN POLYVALENT CONTRE LA NEUROTOXINE DU $i(CLOSTRIDIUM BOTILINUM) |
-
1999
- 1999-07-20 AU AU46412/99A patent/AU4641299A/en not_active Abandoned
- 1999-07-20 WO PCT/IB1999/001301 patent/WO2000005252A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4292307A (en) * | 1977-09-30 | 1981-09-29 | Zemlyakova Valentina P | Vaccine and method for prophylaxis and treatment of clostridioses of animals and poultry |
WO1996041881A1 (fr) * | 1995-06-12 | 1996-12-27 | Microbiological Research Authority | Toxine botulinique de type f et son utilisation |
WO1998007864A1 (fr) * | 1996-08-23 | 1998-02-26 | Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) | Fragments de toxines recombines |
WO1998008540A1 (fr) * | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | VACCIN POLYVALENT CONTRE LA NEUROTOXINE DU $i(CLOSTRIDIUM BOTILINUM) |
Non-Patent Citations (1)
Title |
---|
MORIISHI K ET AL: "Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms", BIOCHIMICA BIOPHYSICAL ACTA, vol. 1307, 1996, pages 123 - 6, XP000857076 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7705124B2 (en) | 2000-07-21 | 2010-04-27 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
CN100457777C (zh) * | 2000-07-21 | 2009-02-04 | 阿勒根公司 | 基于亮氨酸的基序和梭菌神经毒素 |
WO2002008268A2 (fr) * | 2000-07-21 | 2002-01-31 | Allergan, Inc. | Motif a base de leucine et neurotoxines clostridiales |
US7723480B2 (en) | 2000-07-21 | 2010-05-25 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US7705125B2 (en) | 2000-07-21 | 2010-04-27 | Allergan, Inc. | Leucine-based motif and Clostridial neurotoxins |
US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US7534863B2 (en) * | 2000-07-21 | 2009-05-19 | Allergan, Inc. | Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins |
US7671177B2 (en) | 2000-07-21 | 2010-03-02 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US7691974B2 (en) | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US7691983B2 (en) | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
EP1849801A1 (fr) * | 2000-07-21 | 2007-10-31 | Allergan Sales, Inc. | Motif à base de tyrosine et neurotoxines clostridiales |
WO2002008268A3 (fr) * | 2000-07-21 | 2003-02-20 | Allergan Inc | Motif a base de leucine et neurotoxines clostridiales |
US7393925B2 (en) | 2000-07-21 | 2008-07-01 | Allergan, Inc. | Leucine-based motif and Clostridial neurotoxins |
US8008465B2 (en) | 2000-07-21 | 2011-08-30 | Allergan, Inc. | Nucleic acids encoding chimera botulinum toxin type E |
US8017741B2 (en) | 2000-07-21 | 2011-09-13 | Ester Fernandez-Salas | Chimera botulinum toxin type E |
US8206723B2 (en) | 2000-07-21 | 2012-06-26 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US8445650B2 (en) | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
WO2019126542A1 (fr) * | 2017-12-20 | 2019-06-27 | Allergan, Inc. | Polypeptides du domaine de liaison cellulaire de toxine botulique et procédés d'utilisation pour des traitements de troubles associés à la fibrose |
CN112351991A (zh) * | 2017-12-20 | 2021-02-09 | 阿勒根公司 | 肉毒杆菌毒素细胞结合结构域多肽及其用于治疗纤维化相关障碍的方法 |
WO2019152380A1 (fr) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production de neurotoxines de botulinum à l'aide de systèmes bacillus |
CN111971294A (zh) * | 2018-01-30 | 2020-11-20 | 儿童医学中心公司 | 使用芽孢杆菌系统产生肉毒神经毒素 |
Also Published As
Publication number | Publication date |
---|---|
AU4641299A (en) | 2000-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Billington et al. | The Arcanobacterium (Actinomyces) pyogenes hemolysin, pyolysin, is a novel member of the thiol-activated cytolysin family | |
Wu et al. | Protective immunity conferred by recombinant Pasteurella multocida lipoprotein E (PlpE) | |
Cárdenas et al. | Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors | |
CA2365915C (fr) | Vaccin de toxine a/toxine b recombinees contre le clostridium difficile | |
EP0892054B1 (fr) | Vaccine contre clostridium perfringens | |
Vazquez-Boland et al. | Purification and characterization of two Listeria ivanovii cytolysins, a sphingomyelinase C and a thiol-activated toxin (ivanolysin O) | |
CN111925426B (zh) | 一种产气荚膜梭菌α毒素突变体、表达系统、制备方法及应用 | |
US8147841B2 (en) | Clostridium toxin, and process for the preparation of immunogenic composition | |
WO2000005252A1 (fr) | Vaccin comportant un derive immunogene non toxique de la neurotoxine clostridium botulinum du type d | |
US20020054883A1 (en) | Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof | |
Foynes et al. | Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F HC fragment | |
US6783764B1 (en) | Actinobacillus pleuropneumoniae subunit vaccine | |
AU2001259138B2 (en) | Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof | |
Moore et al. | Foreign gene expression in Corynebacterium pseudotuberculosis: development of a live vaccine vector | |
EP1518558B1 (fr) | Vaccin contre l'infection par Actinobacillus pleuropneumoniae comprenant la toxine ApxIV purifiée | |
CN111978380A (zh) | 野生型气肿疽梭菌细胞毒素a及其制备方法、应用和疫苗 | |
Shin et al. | Expression of apxIA of Actinobacillus pleuropneumoniae in Saccharomyces cerevisiae | |
CN110041437A (zh) | 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白 | |
Chacón et al. | Heterologous expression of the cuticular glutathione peroxidase of lymphatic filariae in an attenuated vaccine strain of Salmonella typhimurium abrogates H‐2 restriction of specific antibody responses | |
WO1999045119A2 (fr) | Fabrication de polypeptides mycobacteriens par une bacterie d'acide lactique | |
NZ233138A (en) | Phospholipase toxin from corynebacterium pseudotuberculosis, recombinant product and vaccine | |
CA2543548A1 (fr) | Systeme d'expression | |
AU2002301780B2 (en) | Clostridium toxin and method for preparing immunogenic compositions | |
Kozuka et al. | Expression and secretion of the S2 subunit of pertussis toxin in Bacillus brevis | |
AU764620B2 (en) | Expression system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |